TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens
Diagnostic Cytopathology · 2024
DOI: 10.1002/dc.25359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostic Cytopathology, 2024. Verfasst von Amr Ali und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immunohistochemistry, Repressor Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Introduction
Trichorhinophalangeal syndrome type 1 (TRPS1) has emerged as a reliable immunohistochemistry (IHC) marker for identifying breast origin in metastatic carcinomas. This study investigates the utility of TRPS1 IHC in non‐breast cytology specimens. Materials and Methods A retrospective search of our pathology database for the year 2021 identified fluids (pleural and peritoneal) and liver, lung and bone fine needle aspirations (FNAs) with surgical follow‐up confirming non‐breast metastatic carcinomas. Cell blocks from cases with sufficient neoplastic cells underwent immunostaining using a rabbit polyclonal antibody against human TRPS1. Cases lacking tumor on deeper levels after the original work‐up were excluded from the study. Two pathologists independently interpreted the TRPS1 staining.
Results
Of 136 cases assessed, 31 (22.79%) exhibited positive TRPS1 staining, while 105 (77.21%) were nonreactive. Positivity rates were observed in tumors of Mullerian cell origin, gastrointestinal tract (GIT), and lung origin at 28.85%, 25%, and 21.57%, respectively. Of the tumors of Mullerian cell origin 10 (66.67%) were serous carcinomas, 4 (26.67%) were endometrioid carcinomas, and one (6.67%) was a clear cell carcinoma. Lung tumors comprised seven (63.64%) squamous cell carcinomas and four (36.36%) adenocarcinomas, while the gastrointestinal tumors consisted of 14 (80%) adenocarcinomas and one (20%) squamous cell carcinoma.
Conclusions
Although recognized as a sensitive marker for mammary carcinomas, TRPS1 immunostaining was also detected in Mullerian, lung, and GIT carcinomas. This highlights the significance of being cautious when depending solely on TRPS1 immunostaining to distinguish metastatic breast tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
ORCID-Profile: Amr Ali, Seema Khutti, Kasturi Das
Zitieren
APA
Ali, A., Geetha, S., Wu, D., Chau, K., Karam, P., Khutti, S., Fayyaz, S. S., Das, K., Gimenez, C., & Rosca, O. C. (2024). TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens. Diagnostic Cytopathology. https://doi.org/10.1002/dc.25359
Vancouver
Ali A, Geetha S, Wu D, Chau K, Karam P, Khutti S, et al. TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens. Diagnostic Cytopathology. 2024. doi:10.1002/dc.25359
BibTeX
@article{Ali2024,
author = {Ali, Amr and Geetha, Saroja and Wu, Dongling and Chau, Karen and Karam, Priyanka and Khutti, Seema and Fayyaz, Silvat-Sheik and Das, Kasturi and Gimenez, Cecilia and Rosca, Oana C},
title = {TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens},
journal = {Diagnostic Cytopathology},
year = {2024},
doi = {10.1002/dc.25359}
}
EUVIMED